Current Situation
- One in nine men will be diagnosed with prostate cancer
- Over 190,000 men were diagnosed with prostate cancer in the US and 30,000 men died of the disease, numbers that are expected to grow
- PSA score is often used as the primary predictor of prostate cancer risk
- PSAD* is a better predictor of prostate cancer risk
The Challenges
- PSA may result in over 75% false positives as it cannot distinguish between benign and serious cancers
- PSAD is difficult to calculate until very late in the diagnostic process
- As a result, many unnecessary biopsies are performed due to PSA false positive results
- Unnecessary biopsies and treatments often result in serious negative patient outcomes and high medical costs
The Solution
- ProstaMetrix calculates early, consistent measures of prostate volume
- Early measures of prostate volume allow early PSAD-based diagnosis and treatment decisions
- Better patient outcomes at lower overall cost
- Prostate volume also helps clinicians assess and treat other prostate issues
The Value
For the Patient
- Avoid cost, discomfort and quality of life issues from unnecessary biopsies and treatments
- More reliably monitor prostate health
For Clinicians
- Serve more patients in the ambulatory setting and appropriately triage them for more accurate diagnosis and treatment
- Provide a more effective system to identify and more appropriately refer patients to a higher level of care
For Payers
- Reduce unnecessary procedures and treatments and improve patient outcomes
To learn more about how our solutions can improve
your medical process, contact us.
